CD274 and non-small cell lung carcinoma: ICIs are now part of the first-line NSCLC treatment strategy as monotherapy, combined with chemotherapy, or after definite chemotherapy in patients with stage III unresectable NSCLC accompanied by PD-L1 expression [8,9].